Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Joyce Sutcliffe Senior Vice President at Tetraphase to Speak at Anti-Infectives Partnering Summit October in Boston - GTCbio’s Anti-Infectives Partnering & Deal-Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives
Joyce Sutcliffe Senior Vice President at Tetraphase to Speak at Anti-Infectives Partnering Summit October in Boston

 

PRZOOM - /newswire/ - Boston, MA, United States, 2010/08/14 - GTCbio’s Anti-Infectives Partnering & Deal-Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Joyce Sutcliffe, Senior Vice President of Biology at Tetraphase, will give a featured presentation on “TP-434: A Novel, Gram-Negative Antibiotic in Clinical Development” at the 7th Anti-Infectives Partnering and Deal-making Summit to be held in Boston, MA on October 7-8, 2010 by GTCbio. Infections caused by multidrug-resistant (MDR) gram-negative bacterial pathogens cause great morbidity and mortality worldwide, with a recent study concluding that the spread of resistant pathogens has resulted in higher healthcare and societal costs of $13.5 billion dollars annually in the US. TP-434, a novel fluorocycline, was discovered using a break-through chemistry platform that forms the basis of Tetraphase’s proprietary product engine. TP-434 shows potent activity against a broad range of MDR aerobic and anaerobic gram-negative and gram-positive pathogens both in vitro and in vivo in a variety of murine infection models challenged with MRSA, Streptococcus pneumoniae, S. pyogenes or MDR gram-negative bacteria. With its excellent plasma exposure, volume of distribution, and 40-hour half-life, TP-434 has great potential as a once-daily treatment for serious bacterial infections, especially those caused by MDR gram-negative pathogens.

Also presenting at the 7th Anti-Infectives Partnering and Deal-Making Summit are prestigious organizations including Novartis, Decision Resources, Tufts University, Allliance for Prudent Uses of Antibiotics, Knobbe Martens Olson & Bear, IDSA, PolyMedix, Baselia, AstraZeneca, Pfizer, Trius Therapeutics, Eli Lilly, Tetraphase and other leaders in the industry.

GTCbio’s Anti-Infectives Partnering & Deal-Making Summit is an infectious disease partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, explore potential collaborations, and learn about relevant anti-infective issues and deals that will affect the industry. This event also provides a unique venue for attendees to learn about the anti-infective business development trends, the infectious disease markets, and novel technologies that shape up the industry.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Joyce Sutcliffe Senior Vice President at Tetraphase to Speak at Anti-Infectives Partnering Summit October in Boston

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today